A Persistent Trend Traders Are Watching

Biotech and healthcare-related names are quietly carrying leadership while broader averages stall, with selective rotation highlighting where institutional capital is concentrating. Companies supporting clinical trials and healthcare services are seeing steady tape interest, favoring stocks that sustain orderly patterns of accumulation rather than headline-driven spikes. Liquidity appears disciplined, rewarding names with consistent activity and clear structural strength. Traders are watching this quietly, noting which operators in the sector maintain higher highs on steady volume.

Iqvia Holdings (IQV), a provider of advanced analytics, technology solutions, and contract research services for the healthcare and life sciences sectors, is one of the names standing out. Its 21-day EMA has remained above the 63-day EMA since the initial crossover last July, signaling that the short-term trend aligns with the longer-term trajectory. IQV has consistently held above both EMAs, stair-stepping higher through a series of higher highs and higher lows. For traders, this is a textbook example of a stock maintaining persistent technical leadership.

📈 Want fresh, actionable options ideas each week? Subscribe to our Flagship Optioneering Newsletter and stay ahead of the market. 🧠

From a tactical standpoint, IQV is currently well positioned for a call option trade to gain defined exposure to the ongoing trend. The pattern of orderly upward movement, combined with the fact that it is not overextended, suggests an entry that balances participation and risk. Hypothetically, a near-term call option could offer meaningful leverage, with upside participation contingent on continued price strength. Downside exposure would be limited to the option premium, allowing a controlled approach to capitalizing on the established trend.

To take this kind of step-by-step approach further, we’re hosting a special session this Monday: the Six-Figure Trading Challenge. Attendees will see exactly how we structure trades and plan to scale a consistent strategy toward six-figure potential in 2026. Spots are limited—register now to secure your seat and follow along with the full blueprint.

Wishing You the Best in Investing Success,